Patients For Affordable Drugs NOW (@P4ADNOW) header
Patients For Affordable Drugs NOW (@P4ADNOW) profile picture

P4ADNow is a bipartisan patient advocacy organization fighting for lower drug prices. We mobilize patients in support of legislation to fix our broken system.

Washington, DC
Joined December 2017
Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)Photo by Patients For Affordable Drugs NOW (@P4ADNOW)
NEW VIDEO: We just released a new video explaining one of the most important — and least talked about — drivers of high drug prices: patent abuse. The ETHIC Act would close the loopholes drug companies exploit to block cheaper generics. Watch, share, and urge Congress to act: tinyurl.com/e3kr3vv2
2
1
2
1,413
“I have to choose between food and medication.” During today’s Senate Judiciary Committee hearing, P4AD CEO Merith Basey shared the story of Kevin, a young Oregon man living with Crohn’s disease who relies on Rinvoq, a medication with a list price of more than $7,000 per month. Kevin has faced bills of up to $2,000, gone without medication because he couldn't afford it, and never achieved full remission. Meanwhile, Rinvoq is protected by a thicket of overlapping patents that delays lower-cost competition, leaving patients like Kevin with fewer affordable treatment options. Kevin's story shows why patent reform matters. Congress must advance bipartisan reforms that curb Big Pharma's patent abuse, increase competition, and lower prescription drug prices. Patients can't afford to wait. Learn more at P4ADNOW.ORG.
1
2
86
“The choice is not between innovation and affordability. Patients need both.” P4AD CEO Merith Basey testified before the Senate Judiciary Committee, urging Congress to advance bipartisan reforms that curb Big Pharma’s patent abuse, increase competition, and lower prescription drug prices. The patent system should reward companies for developing new treatments, not for exploiting loopholes to extend monopolies on existing drugs. Congress can help restore that balance by advancing bipartisan reforms that protect genuine innovation, increase competition, and lower drug prices for patients. Watch Merith’s full testimony and learn more at P4ADNOW.ORG.
1
1
74
When brand-name drug companies pay or incentivize potential competitors to delay launching cheaper generic versions of their medications, they extend their monopolies and keep affordable alternatives off the market. This is called a “pay-for-delay” deal, and they are used to keep prescription drug prices high. As the Senate Judiciary Committee prepares to examine competition in the prescription drug market on Tuesday, these shady deals are an important part of the conversation. Visit PatientsPushForCompetition.O… to learn more
51
Tomorrow, P4ADNow CEO Merith Basey will testify before the Senate Judiciary Committee, bringing patients’ stories to Capitol Hill and urging Congress to take action against Big Pharma’s patent abuse. Drug companies exploit loopholes in the patent and regulatory systems to block competition, keep lower-cost alternatives off the market, and drive up prescription drug prices. Merith will call on lawmakers to advance bipartisan reforms that will tackle pay-for-delay agreements, product hopping, patent thickets, and other abuses that keep medications out of reach for millions of patients. Congress must act to ensure the patent system rewards genuine innovation—not corporate abuse—and allows competition to bring down drug prices. tinyurl.com/yp447ya3
54
Big Pharma has used patent thickets to protect its monopolies, delay competition, and keep prescription drug prices high. The ETHIC Act would address a key tactic behind patent thickets by restricting certain forms of double patenting, making it easier for lower-cost generic and biosimilar competitors to come to market. As the Senate Judiciary Committee prepares to examine competition in the prescription drug market on Tuesday, patent thickets are an important part of the conversation. Help us fight Big Pharma patent abuse! Send a letter to your representative urging them to put patients first by supporting the ETHIC Act today: tinyurl.com/3bynbf37
1
60
CEO Merith Basey will testify at Tuesday's Senate Judiciary Committee hearing; P4AD joined the ERISA Industry Committee in a letter urging congressional leaders to pass the bipartisan ETHIC Act; leaders on key health committees sent letters this week to the 27 companies demanding the unredacted terms of the TrumpRx deals, and P4AD CEO Merith Basey joined Punchbowl News for a briefing on prescription drug access and affordability. Read more at our Week in Review: tinyurl.com/yv7f4c2h Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
45
Big Pharma exploits the patent system to block lower-cost competition and keep prescription drug prices high. P4AD's Merith Basey explains some of the tactics drug companies use to protect their profits while patients pay the price. Want to learn more about the practices keeping prescription drugs unaffordable and what you can do about them? 📩 Sign up for updates from P4AD: actionnetwork.org/forms/base…
1
43
Big Pharma warned that Medicare drug price negotiation would undermine investment in new medicines. But the evidence doesn’t support those claims. Dr. Aaron Kesselheim explains why the industry’s predictions about the impact of the law on innovation haven’t materialized. Patients on both sides of the aisle fought hard for the reforms in the 2022 prescription drug law and shouldn’t fall for drug industry fear-mongering intended to block drug price reforms.
1
60
A new look. The same mission. 👀 We’ve been working behind the scenes on something exciting at Patients For Affordable Drugs NOW, and we can’t wait to share it with you. Our new website is almost here! Stay tuned. 💻
42
The Week in Review in Prescription Drug Pricing: Negotiation Final Rule, CVS Breaks Up, and Keytruda Biosimilar Troubles. Read more at our Week in Review: tinyurl.com/y546nw97
42
The ETHIC Act would reduce drug company patient abuse by addressing duplicative patenting, but Big Pharma's lobbyists are hard at work trying to stop it from passing. Help us fight Big Pharma greed. Send a letter to your representative urging them to put patients first by supporting the ETHIC Act today: tinyurl.com/3bynbf37
1
1
1
121
Something really exciting is launching soon 👀 Explainers, ways to take action, educational materials, and so much more — all in one place. Stay tuned for more!
1
69
The nation's largest pharmaceutical companies rake in billions in profit, and their CEOs take home millions in compensation. Meanwhile, 1 in 3 Americans struggles to afford their prescription medication. As Sen. Sanders points out, there’s something deeply wrong with a system that delivers enormous profits for Big Pharma while leaving patients unable to access the medicines and treatments they need. Visit P4AD.ORG to fight back!
1
37
The third round of Medicare drug price negotiations will end on November 1, five days before the midterms and healthcare costs remain a major voter concern, with polling showing they could influence decisions at the ballot box, and CMS will broaden the agency’s Cell and Gene Therapy Access Model beyond Genetix Biotherapeutics and Vertex’s sickle cell disease therapies. Read more at our Week in Review: tinyurl.com/mak8u7eb Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
53
Patients For Affordable Drugs NOW retweeted
🚨Exciting healthcare affordability news!!! 🚨 Patent thickets are a major obstacle to biosimilar drugs entering the market (which lower costs). Biologic medicines in particular are a massive cost driver of prescription drug spending for everyone, despite being used by less patients with less frequency than nonbiologic generics. Because loopholes in the patent process (federal law) are the problem here, allowing lawsuits to be structured en masse and sequentially in a massive delay tactic scam, only Congressional action can fix this problem. So this bipartisan bill is a long overdue policy solution that will absolutely lower drug prices on some of our most unaffordable drugs, leading to lower pharmaceutical spend by employers and ultimately lower healthcare costs for all. Kudos to @SenPeterWelch @HawleyMO @amyklobuchar @RepArrington!! Let’s all get behind them and get the Ethic Act passed!!!!
What's one of the biggest drivers of high drug prices? 🤔 Big drug company patent abuse. The P4AD-endorsed ETHIC Act would close a loophole drug companies exploit to block cheaper generics from coming to market and lowering costs for patients. Watch, share, and urge Congress to act: tinyurl.com/hrdw4ctz
2
2
6
500
Patients For Affordable Drugs NOW retweeted
We're currently in the lead for a 2026 Anthem Award, but the competition is catching up! Selected from more than 2,500 projects, we’re proud to see this work recognized alongside other campaigns driving social impact. But we need your help! Voting is open through October 29. Don’t forget to verify your email after voting to make sure your vote counts! Thank you for helping us keep up the fight for lower prescription drug prices! #AnthemAwards @anthemawards celebrate.anthemawards.com/P…
1
1
94
CVS owns pharmacies, operates one of the country's largest PBMs, and controls a major health insurer. As Rep. Ocasio-Cortez explains, this kind of market concentration raises serious questions about competition, costs, and who benefits. Patients across the country are struggling to afford their medications. We need more transparency and accountability across the prescription drug supply chain to bring costs down.
1
91
There are several bipartisan bills in Congress right now that could help bring down the cost of prescription drugs. Drug companies deploy manipulative tactics to delay or block lower-cost competition to keep their prices high P4AD has been pushing for legislation to address some of Big Pharma’s patent schemes. Help us rein in the pharmaceutical industry’s monopoly power. Urge your Senators to support patent reform. Take action today by sending a letter! actionnetwork.org/letters/te…
1
60
Launch price of drugs jumped 35% between 2022-2025, after the Fifth Circuit rejected PhRMA’s challenge this summer, the group filed an en banc petition, and Maryland Gov. backed legislation allowing the state’s PDAB to set upper payment limits based on prices negotiated by Medicare. Read more at our Week in Review: tinyurl.com/3pyshntz Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
38
Big Pharma's abuse of the patent system has made it harder for generics and biosimilars to come to market to lower drug prices for patients, but the bipartisan Eliminating Thickets to Improve Competition (ETHIC) Act could help change that. The ETHIC Act addresses double patenting by allowing a generic manufacturer to challenge only one key patent in a patent family to invalidate duplicative patents. Helping to close a loophole that Big Pharma has relied on to block competition and keep prices artificially high. Big Pharma’s army of lobbyists is working to stop common-sense reforms like the ETHIC Act. Make sure they don’t get their way -- send a letter to your representative urging them to support ETHIC today: tinyurl.com/3bynbf37
1
3
102